CI 1015Alternative Names: PD 145942
Latest Information Update: 19 Jul 2002
At a glance
- Originator Pfizer
- Class Anxiolytics
- Mechanism of Action Cholecystokinin B receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 11 Feb 1998 Preclinical development for Anxiety disorders in United Kingdom (Unknown route)